Pharma major Lupin Limited (Lupin) announced that it has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Syprine® Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin's Nagpur (Unit 1) facility, India.
Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.
Trientine Hydrochloride Capsules USP (RLD: Syprine®) had an annual sales of approximately USD 86 million in the U.S. (IQVIA MAT March 2020).
Shares of LUPIN LTD. was last trading in BSE at Rs.883.9 as compared to the previous close of Rs. 873.4. The total number of shares traded during the day was 84304 in over 4111 trades.
The stock hit an intraday high of Rs. 889 and intraday low of 865.85. The net turnover during the day was Rs. 74040565.